CLAIMS

1. Transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients and containing estradiol and norethisterone acetate, ~~which~~ reservoir is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino-containing polymer.

2. Transdermal therapeutic system according to Claim 1, ~~characterized in that~~ the crystallization inhibitor is selected from polymers based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, ~~in particular in~~ a molar ratio of 1:2:1, polyaminoamides, polyaminoimidazolines, polyetherurethaneamines, polyamines and polyglucosamines.

3. Transdermal therapeutic system according to either of Claims 1 and 2, characterized in that the reservoir comprises one or more crystallization inhibitors in a proportion of from 0.05-30% by weight.

4. Transdermal therapeutic system according to one or more of Claims 1 - 3, characterized in that the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, preferably from 1:3 to 1:7, and in an overall concentration of up to 25% by weight.

5. Transdermal therapeutic system according to ~~one or more of Claims 1 - 4~~, ~~characterized in~~ that the reservoir includes a constituent from the group of ageing inhibitors,

plasticizers, antioxidants and absorption improv rs, the plasticizer being us d in a concentration of 0-5% by weight and the ageing inhibitor in a concentration of 0.1-2% by weight.

6. Transdermal therapeutic system according to ~~one or more of Claims 1 - 5, characterized in that~~ the pressure-sensitive adhesive is a solvent-based adhesive, a dispersion adhesive, a hot-melt adhesive ~~or~~ a UV-crosslinkable adhesive.

7. Transdermal therapeutic system according to ~~one or more of Claims 1 - 6, characterized in that~~ the reservoir consists of ~~two or more~~ layers.

8. Transdermal therapeutic system according to one or more of Claims 1 - 7, characterized in that the reservoir has a layer thickness of 0.02 mm-0.500 mm, preferably 0.030-0.200 mm.

9. Transdermal therapeutic system according to ~~one or more of Claims 1 - 8, characterized in that~~ the reservoir is provided with an additional pressure-sensitive adhesive layer ~~and/or with a pressure-sensitive adhesive margin.~~

10. Use of the transdermal therapeutic system corresponding to one or more of Claims 1-9 for therapeutic applications in human medicine.